Silence Therapeutics (NASDAQ: SLN) — Perfil da empresa, notícias e dados financeiros
Silence Therapeutics develops precision-engineered RNA-based medicines targeting serious diseases with a focus on genetic treatments.
Silence Therapeutics
Silence Therapeutics (OTCMKTS:SLNCF), (NASDAQ:SLN) specializes in the development of precision-engineered medicines for the treatment of serious diseases with unmet medical needs, focusing on the use of RNA technology to inhibit or "silence" disease-causing genes. The company's innovative approach aims to revolutionize treatment for patients by targeting the root causes of diseases at the genetic level. Silence Therapeutics is actively pursuing a diverse range of projects, including proprietary and partnership-based programs, to develop novel therapeutic agents. The objective of the company is to advance its pipeline of RNA-based therapies to clinical development and bring transformative treatments to patients around the world. Silence Therapeutics is committed to pushing the boundaries of genetic medicine to improve health outcomes for future generations.
Resumo
Operações
Produtos e/ou serviços de Silence Therapeutics
- SLN124 for treating thalassemia and myelodysplastic syndrome, targeting TMPRSS6 to regulate iron balance.
- SLN360 aimed at addressing cardiovascular disease by reducing Lipoprotein(a) levels, with potential to lower heart attack and stroke risk.
- SLN500, leveraging a partnership with Takeda to develop siRNA therapies targeting rare genetic diseases.
- RNAi technology platform designed to silence disease-causing genes, offering broad therapeutic applications across various conditions.
- Messenger RNA delivery technology that improves the delivery and effectiveness of RNA molecules, enhancing treatment efficacy.
- Customized siRNA molecules developed for partners, targeting a wide range of diseases, showcasing versatility in gene silencing.
equipe executiva do Silence Therapeutics
- Iain Gladstone RossInterim CEO & Chairman of the Board
- Rhonda L. HellumsExecutive VP, CFO, Secretary & Executive Director
- Steven J. RomanoExecutive VP and Chief Research & Development Officer
- Marie Wikstrom LindholmChief Scientific Officer
- Gem Gokmen HopkinsHead of IR & Corporate Communications
- Jaimin B. ShahSVP & General Counsel
- J.P. GabrielChief Technical Operations Officer
- Curtis RambaranChief Medical Officer
Últimas notícias sobre a Silence Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Silence Therapeutics , em USD.
- Cap. de mercado
- 1,2 bi
- Receita (TTM)
- 615 mil
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 559 mil | -89,8 mi | -88,6 mi | |
| 43,3 mi | -63,3 mi | -45,3 mi | |
| 25,4 mi | -49,6 mi | -43,3 mi | |
| 17,7 mi | -49,8 mi | -41 mi |